×

Sarepta CEO: Study shows we're on the right path to treat muscular dystrophy

8:20 AM ET Wed, 6 Sept 2017

Doug Ingram, Sarepta Therapeutics president and CEO, talks about the company's positive study results for treatment of Duchenne muscular dystrophy.